Calliditas IPO To Support Phase III Berger's Disease Study
Executive Summary
Calliditas is aiming to raise new funding in an IPO and listing on Nasdaq Sweden to support late-stage clinical development and commercialization of its Berger's disease candidate, and studies in additional indications.
You may also be interested in...
Finance Watch: Genmab Launches This Year's Biggest Biopharma IPO In The US
Public Company Edition: Genmab raised $505.9m while other 17 July IPOs from Fulcrum and Mirum grossed $72m and $75m, respectively. Also, Horizon sells notes to pay down debt and Inovio reduces its workforce by 28%.
Pharmalink’s $15M Series C Financing To Progress Assets And Strategy
Privately held Pharmalink of Sweden will use a $15 million Series C funding for pivotal studies in its lead cancer and renal disease drugs, and to shop for new in-licensing or M&A opportunities in the Nordic region.
First Phase III Data For Inovio's Immunotherapy VGX-3100 Encouraging In Cervical Dysplasia
Inovio Pharmaceuticals has reported promising initial data from its first Phase III study of its electrical current-driven DNA plasmid-based immunotherapy, VGX-3100, in virus-associated cervical dysplasia; it is heading a small group of companies evaluating novel therapies in the condition, which often advances to cancer.
Need a specific report? 1000+ reports available
Buy Reports